News and events

  • All
  • Events
  • Press release
  • Publication
Press release

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors (EN/FR/NL)

Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022

Triple mode of action dengue fever program identified for development
Industry veteran with exceptional leadership experience to support
ExeVir’s new progressive pipeline against infectious diseases

Read More
Press release

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.

Read More
Press release

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

Read More
Events

8th Annual HealthTech Investment Forum — 5-6 October 2021

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

Read More
Events

Bio Europe — 25-27 October 2021

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

Read More